HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.

Abstract
Recruitment of Fc-receptor-bearing effector cells, such as natural killer (NK) cells, is a feature critical for the therapeutic success of antitumor antibodies and can be improved by the modifications of an antibody's Fc part. The various ligands of the activating immunoreceptor NKG2D, NKG2DL) are selectively expressed on malignant cells including leukemia. We here took advantage of the tumor-associated expression of NKG2DL for targeting leukemic cells by NKG2D-immunoglobulin G (IgG)1 fusion proteins containing modified Fc parts. Compared to NKG2D-Fc containing a wild-type Fc part (NKG2D-Fc-WT), our mutants (S239D/I332E and E233P/L234V/L235A/ΔG236/A327G/A330S) displayed highly enhanced (NKG2D-Fc-ADCC) and abrogated (NKG2D-Fc-KO) affinity to the NK cell Fc receptor, respectively. Functional analyses with allogenic as well as autologous NK cells and primary malignant cells of leukemia patients revealed that NKG2D-Fc-KO significantly reduced NK reactivity by blocking immunostimulatory NKG2D-NKG2DL interaction. NKG2D-Fc-WT already enhanced antileukemia reactivity by inducing antibody-dependent cellular cytotoxicity (ADCC) with NKG2D-Fc-ADCC mediating significantly stronger effects. Parallel application of NKG2D-Fc-ADCC with Rituximab caused additive effects in lymphoid leukemia. In line with the tumor-associated expression of NKG2DL, no NK cell ADCC against resting healthy blood cells was induced. Thus, NKG2D-Fc-ADCC potently enhances NK antileukemia reactivity despite the inevitable reduction of activating signals upon binding to NKG2DL and may constitute an attractive means for immunotherapy of leukemia.
AuthorsJulia Steinbacher, Katrin Baltz-Ghahremanpour, Benjamin Joachim Schmiedel, Alexander Steinle, Gundram Jung, Ayline Kübler, Maya Caroline André, Ludger Grosse-Hovest, Helmut Rainer Salih
JournalInternational journal of cancer (Int J Cancer) Vol. 136 Issue 5 Pg. 1073-84 (Mar 01 2015) ISSN: 1097-0215 [Electronic] United States
PMID25046567 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2014 UICC.
Chemical References
  • Immunoglobulin Fc Fragments
  • Immunoglobulin G
  • KLRK1 protein, human
  • NK Cell Lectin-Like Receptor Subfamily K
  • Recombinant Fusion Proteins
Topics
  • Antibody-Dependent Cell Cytotoxicity
  • Cytotoxicity, Immunologic (immunology)
  • Humans
  • Immunoglobulin Fc Fragments (genetics, immunology)
  • Immunoglobulin G (genetics, immunology)
  • Immunotherapy
  • Killer Cells, Natural (immunology, pathology)
  • Leukemia (genetics, immunology, pathology)
  • NK Cell Lectin-Like Receptor Subfamily K (genetics, immunology)
  • Recombinant Fusion Proteins (genetics, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: